Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Chronic HCV Genotype 3

Published byJob Sherman Modified over 8 years ago

Similar presentations

Presentation on theme: "Treatment of Chronic HCV Genotype 3"— Presentation transcript:

1 Treatment of Chronic HCV Genotype 3
Robert G. Gish MD Staff Physician, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona Clinical Professor of Medicine, University of Nevada, Las Vegas Medical Director, Hepatitis B Foundation Vice Chair, Executive Committee, National Viral Hepatitis Roundtable (NVHR) Last Updated: May 14, 2014

2 Treatment of Chronic HCV Genotype 3
Background and Definitions Initial Treatment and Retreatment of Prior Relapsers Retreatment of Prior Nonresponders Issues and Controversies Future Therapies Summary

3 Background and Definitions
Treatment of Chronic Hepatitis C: Genotype 3 Background and Definitions

4 Treatment of Chronic HCV Genotype 3 Background
HCV infects ~ 5 million people in the US today Genotype 3 is the third most common HCV genotype in US Up to 85% of patients have contraindications for interferon therapy Major linkage to IVDA in epidemiological studies Interferes with lipid metabolism in hepatocytes and linked with fatty liver Slightly higher risk of developing cirrhosis HCV Geno 3 is the new Geno 1 in terms of lower response rates

5 Virologic Responses with HCV Therapy Sustained Virologic Response at 12 Weeks Post Therapy (SVR12)
Treatment Post Treatment SVR12 End of Treatment 12 Weeks Undetectable Sustained Virologic Response (SVR12) = Undetectable HCV RNA 12 Weeks Post Treatment

6 Different Types of Virologic Failure with HCV Therapy
Virologic Responses with HCV Therapy Relapser and Nonresponder (Null and Partial) Different Types of Virologic Failure with HCV Therapy Treatment Relapser Nonresponder Null Responder Nonresponder Partial Responder Undetectable

7 AASLD/IDSA/IAS-USA 2014 HCV Treatment Recommendations Criteria for Interferon Ineligible
Interferon Ineligible is defined as one or more of the following: Intolerance to interferon Autoimmune hepatitis and other autoimmune disorders Hypersensitivity to peginterferon or any of its components Decompensated hepatic disease Major uncontrolled depressive illness A baseline neutrophil count below 1500/μL, a baseline platelet count below 90,000/μL or baseline hemoglobin below 10 g/dL A history of preexisting cardiac disease Source: AASLD/IDSA/IAS-USA ( Accessed May 12, 2014

8 Treatment-Naïve and Prior Relapsers
Treatment of Chronic Hepatitis C: Genotype 3 Treatment-Naïve and Prior Relapsers

9 AASLD/IDSA/IAS-USA 2014 HCV Treatment Recommendations Initial Therapy for Patients with Genotype 3 Chronic HCV Patients with GT 3 HCV: Initial Treatment & Retreatment of Relapsers* Recommended Therapy, Regardless of Eligibility for Interferon Therapy Sofosbuvir + Ribavirin x 24 weeks Alternative Therapy, Eligible for Interferon Therapy Sofosbuvir + Peginterferon + Ribavirin x 12 weeks Not Recommended Peginterferon + Ribavirin x weeks Monotherapy with Peginterferon, Ribavirin, or a Direct Acting Antiviral Agent Any Regimen with Telaprevir, Boceprevir, or Simeprevir *Patients who experienced relapse after Peginterferon plus Ribavirin therapy Source: AASLD/IDSA/IAS-USA ( Viewed April 22, 2014

10 Treatment-Naïve & Prior Relapsers with GT3 Chronic HCV Key Studies that Support Treatment Recommendations Sofosbuvir + Ribavirin - FISSION - POSITRON - VALENCE Sofosbuvir + Ribavirin + Peginterferon - PROTON Sofosbuvir + Ribavirin or Sofosbuvir + Ribavirin + Peginterferon - ELECTRON

11 Sofosbuvir + RBV (weight-based) Peginterferon + RBV (fixed-dose)
Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Design Week 12 24 36 Sofosbuvir + RBV (weight-based) N =256 SVR12 Peginterferon + RBV (fixed-dose) N =243 SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Peginterferon alfa-2a: 180 µg once weekly Weight-based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Fixed-dose Ribavirin (in 2 divided doses): 800 mg/day Source: Lawitz E, et al. N Engl J Med ;368:

12 Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Results
SVR12 by Genotype RBV = Ribavirin; PEG = Peginterferon 68/70 52/67 102/183 110/176 170/253 162/243 Source: Lawitz E, et al. N Engl J Med ;368:

13 Sofosbuvir + Ribavirin for HCV GT 2 or 3 (PEG not an option) POSITRON Trial: Design
Week 12 24 Sofosbuvir + RBV 12 weeks N =207 SVR12 Placebo 12 weeks N =71 SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Weight-Based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Jacobson I, et al. N Engl J Med ;368:

14 Sofosbuvir + Ribavirin for HCV GT 2,3 (PEG not an option) POSITRON: Results with Sofosbuvir + Ribavirin SVR12 by HCV Genotype 101/109 60/98 Placebo arm = 0% SVR12 Source: Jacobson I, et al. N Engl J Med ;368:

15 Sofosbuvir + Ribavirin for Treatment Naïve & Experienced HCV GT 2 or 3 VALENCE: Treatment Arms
Week 12 24 36 GT 2 Sofosbuvir + RBV (n = 73) SVR12 GT 3 Sofosbuvir + RBV (n = 250) SVR12 Note: 85 patients enrolled in placebo arm Original Study Protocol: Placebo versus 12 weeks treatment for GT 2 and 3. Amended Protocol: GT3 treatment extended from 12 to 24 weeks; Placebo arm offered alternative treatment Drug Dosing Sofosbuvir 400 mg once daily Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Zeuzem S, et al. N Engl J Med May 4. [Epub ahead of print]

16 SVR12 for Treatment-Naïve GT 3
Sofosbuvir + Ribavirin for Treatment Naïve & Experienced HCV GT 2 or 3 VALENCE: Results for Treatment-Naïve GT 3 with 24 weeks All-Oral Therapy SVR12 for Treatment-Naïve GT 3 Source: Zeuzem S, et al. N Engl J Med May 4. [Epub ahead of print]

17 Sofosbuvir + Peginterferon + Ribavirin in Treatment-Naive Genotypes 1-3 PROTON Trial: Design
Week 12 24 48 72 GT 1 SOF (200 mg) + PEG + RBV PEG + RBV + RVR n = 48 - RVR PEG + RBV SOF (400 mg) + PEG + RBV PEG + RBV + RVR n = 47 - RVR PEG + RBV SOF + PEG + RBV n = 26 GT 2, 3 SOF + PEG + RBV n = 25 Drug Dosing Sofosbuvir (SOF): 400 mg once daily, except as designated in arm that received 200 mg once daily Ribavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Peginterferferon alfa-2a (PEG): 180 µg once weekly N =14 Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

18 SVR 24 by Genotype and Treatment Regimen
Sofosbuvir + Ribavirin + Peginterferon in Treatment-Naive Genotypes 1-3 PROTON Trial: Results SVR 24 by Genotype and Treatment Regimen 41/48 42/47 15/26 23/25 Genotype 1 Genotype 2 or 3 Source: Lawitz E, et al. Lancet Infect Dis. 2013;13:401-8.

19 Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3 ELECTRON Trial (Arms 1-8): Design
Week 8 12 20 24 GT 2,3 Naïve n = 10 SVR12 SOF + RBV n = 9 SVR12 SOF + RBV + PEG (week 1-4) n = 10 SVR12 SOF + RBV + PEG (week 1-8) n = 11 SVR12 SOF + RBV + PEG n = 10 SVR12 SOF n = 10 SVR12 SOF + RBV + PEG GT 1 Null n = 10 SVR12 SOF + RBV GT 1 Naive n = 25 SVR12 SOF + RBV Drug Dosing Sofosbuvir (SOF): 400 mg once daily Ribavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Peginterferon alfa-2a (PEG): 180 µg once weekly N =14 Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

20 Treatment-Naïve Genotype 3
Sofosbuvir and Ribavirin +/- Peginterferon in GT 3 ELECTRON: Subset Analysis SVR 12 for Treatment-Naïve Genotype 3* 6/6 6/6 6/6 7/7 10/10 Treatment-Naïve Genotype 3 *Data for sofosbuvir monotherapy not shown Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

21 Retreatment of Prior Nonresponders
Treatment of Chronic Hepatitis C: Genotype 3 Retreatment of Prior Nonresponders

22 AASLD/IDSA/IAS-USA 2014 HCV Treatment Recommendations Retreatment of Patients with Genotype 3 Chronic HCV Patients with GT 3 HCV: Retreatment of Prior Nonresponders* Recommended Therapy Sofosbuvir + Ribavirin x 24 weeks Alternative Therapy Sofosbuvir + Peginterferon + Ribavirin x 12 weeks Not Recommended Peginterferon + Ribavirin +/- [Boceprevir or Simeprevir or Telaprevir] Monotherapy with Peginterferon, Ribavirin, or a Direct Acting Antiviral Agent Treatment of Decompensated Cirrhosis with Peginterferon *Patients who experienced nonresponse (partial or null) with Peginterferon plus Ribavirin therapy Source: AASLD/IDSA/IAS-USA ( Viewed April 22, 2014

23 Sofosbuvir + Ribavirin - FUSION - VALENCE
Treatment Experienced Nonresponders with GT3 Chronic HCV Key Studies that Support Treatment Recommendations Sofosbuvir + Ribavirin - FUSION - VALENCE Sofosbuvir + Ribavirin + Peginterferon - LONESTAR-2

24 Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Design
Week 12 16 24 28 Sofosbuvir + RBV 12 weeks Placebo N =103 SVR12 Sofosbuvir + RBV 16 weeks N =98 SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Weight-Based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Jacobson I, et al. N Engl J Med ;368:

25 SVR12 for Treatment-Experienced GT3
Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Results for GT3 SVR12 for Treatment-Experienced GT3 19/64 39/63 14/38 25/40 5/26 14/23 SOF = Sofosbuvir; RBV = Ribavirin Source: Jacobson I, et al. N Engl J Med ;368:

26 Sofosbuvir + Ribavirin for Treatment Naïve & Experienced HCV GT 2 or 3 VALENCE: Treatment Arms
Week 12 24 36 GT 2 Sofosbuvir + RBV (n = 73) SVR12 GT 3 Sofosbuvir + RBV (n = 250) SVR12 Note: 85 patients enrolled in placebo arm Original Study Protocol: Placebo versus 12 weeks treatment for GT 2 and 3. Amended Protocol: GT3 treatment extended from 12 to 24 weeks; Placebo arm offered alternative treatment Drug Dosing Sofosbuvir 400 mg once daily Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Zeuzem S, et al. N Engl J Med May 4. [Epub ahead of print]

27 SVR12 for Treatment-Experienced GT 3
Sofosbuvir + Ribavirin for Treatment Naïve & Experienced HCV GT 2 or 3 VALENCE: Results for Treatment Experienced GT 3 SVR12 for Treatment-Experienced GT 3 Source: Zeuzem S, et al. N Engl J Med May 4. [Epub ahead of print]

28 Sofosbuvir + Peginterferon + Ribavirin
Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3 LONESTAR-2 Trial: Design Week 12 24 GT 2 or 3 Sofosbuvir + Peginterferon + Ribavirin N = 47 SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Peginterferon alfa-2a: 180 µg once weekly Ribavirin (weight-based and in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Lawitz E, et al. 64th AASLD; Washington, DC Abstract LB-4.

29 SVR12 in Treatment-Experienced by HCV Genotype
Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3 LONESTAR-2 Trial: Results SVR12 in Treatment-Experienced by HCV Genotype 42/47 22/23 20/24 Source: Lawitz E, et al. 64th AASLD; Washington, DC Abstract LB-4.

30 Issues and Controversies
Treatment of Chronic Hepatitis C: Genotype 3 Issues and Controversies

31 Issues and Controversies
Cost of Therapy Sofosbuvir + PEG + RBV higher SVR than all oral (LONESTAR data) - Treat selected Geno 3 patients with Sofosbuvir + PEG + RBV? - Wait for FDC Ledipasvir-Sofosbuvir + RBV with 100% SVR? When to Defer Therapy - Decisions on when to warehouse? (Non) Role of IL-28b Testing Degree of Liver Fibrosis - How to stage?

32 How is cost of therapy impacting treatment decisions?

33 Hepatitis C Genotype 3 Estimated Medication Costs for Treatment-Naïve & Prior Relapsers
Patients with GT 3 HCV: Initial Treatment & Retreatment of Relapsers Regimen and Duration Regimen Cost Recommended Therapy Sofosbuvir + Ribavirin x 24 weeks $169,000 Alternative Therapy Sofosbuvir + Peginterferon + Ribavirin x 12 weeks $97,000

34 Hepatitis C Genotype 3 Estimated Medication Costs for Retreatment of Nonresponders
Patients with GT 3 HCV: Retreatment of Nonresponders Regimen and Duration Regimen Cost Recommended Therapy Sofosbuvir + Ribavirin x 24 weeks $169,000 Alternative Therapy Sofosbuvir + Peginterferon + Ribavirin x 12 weeks $97,000

35 HCV Therapy for Genotype 3 Chronic HCV Cost Analysis Based on Cost per SVR
Patient Characteristics Regimen Options SVR Cost per SVR Naïve, no cirrhosis SOF + RBV x 24 wks 93% $194,624 SOF + PEG + RBV x 12 wks ? Naïve, cirrhosis 92% $196,739 Treatment experienced, no cirrhosis Wait until….? 85% $212,941 Treatment experienced, cirrhosis 60% $301,667 83% $126,915 Source for Figure: Camilla Graham, MD, MPH. Beth Israel Deaconess Medical Center Data Sources: (1) Lawitz E, et al. NEJM 2013; 368: (2) Jacobson I, et al. NEJM 2013; 368: (3) Antiviral Drugs Advisory Committee Meeting, FDA and Gilead reviews, 10/25/ (4) Package Insert, Gilead.com 12/7/2013

36 Treat now or defer therapy?

37 Factors Favoring Treat Now
Advanced Fibrosis (F3-F4) - Platelet count < 150,000/uL - Large spleen and/or portal vein - Esophageal varices Synthetic dysfunction Systemic disease - Cryoglobulinemia (+RhF) Highly motivated patients/symptoms Patients with Increased Mortality Risk - All cause - HCC risk

38 How do you treat patient that failed Sofosbuvir + Ribavirin?

39 Retreatment of Sofosbuvir + Ribavirin Failure: Features
Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3 Study Features Retreatment of Sofosbuvir + Ribavirin Failure: Features Design: Open-label, study for patients with GT 2 or 3 who had failure with sofosbuvir + ribavirin in FISSION, POSITRON, or FUSION trial Setting: Europe, United States, and Canada Entry Criteria - N = 107 patients with chronic HCV - HCV genotype 2 (10%) or HCV genotype 3 (90%) - Previous relapse on sofosbuvir plus ribavirin - Patients with compensated cirrhosis allowed to enroll Regimens (patients offered 2 possible regimens) - Sofosbuvir + Ribavirin x 24 weeks - Sofosbuvir + Peginterferon + Ribavirin x 12 weeks Primary End-Point: SVR12 Source: Esteban R, et al. 49th EASL; April Abstract 08.

40 GT2 or GT3 Sofosbuvir + PEG + RBV Sofosbuvir + RBV
Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3 Study Design Week 12 24 36 GT2 or GT3 Sofosbuvir + PEG + RBV N = 34 SVR12 Sofosbuvir + RBV N = 73 SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Peginterferon alfa-2a: 180 µg once weekly Weight-based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Esteban R, et al. 49th EASL; April Abstract 08.

41 SVR12 by Regimen and HCV Genotype
Retreatment of SOF + RBV Failure with SOF-Containing Regimens in GT 2 or 3 Results, by Genotype SVR12 by Regimen and HCV Genotype 4/4 1/2 20/22 24/38 Source: Esteban R, et al. 49th EASL; April Abstract 08.

42 Future Treatment Options
Hepatitis C: Genotype 3 Future Treatment Options

43 Future Regimens for GT-3
Ledipasvir + Sofosbuvir - Lepidasvir: NS5A replication inhibitor - Sofosbuvir: NS5B polymerase inhibitor Daclatasvir + Sofosbuvir? - Daclatasvir: NS5A replication inhibitor - Sofosbuvir: NS5B polymerase inhibitor ABT-450/r-Ombitasvir +/- Ribavirin? - ABT-450/r: NS3 protease inhibitor with ritonavir boosting - Ombitasvir (formerly ABT-267): NS5A replication inhibitor

44 Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2: Study Design
Week 12 24 GT1 Prior Sofobuvir n = 19 LDV-SOF + RBV SVR12 GT1 CTP Class B n = 20 LDV-SOF SVR12 GT3 Treatment Naive n = 25 LDV-SOF SVR12 n = 26 LDV-SOF + RBV SVR12 Drug Dosing Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg N =14 Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

45 SVR 12, by GT and Treatment Regimen
Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2: Study Design SVR 12, by GT and Treatment Regimen 19/19 13/20 16/25 26/26 SOF-Experienced CTP Class B Treatment Naive LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

46 Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3 A1444-040 Design: Treatment-Naïve 24 Week Rx
12 24 36 Rx Naïve GT 2 / 3 n = 44 n = 16 SOF × 7 days, then DCV + SOF SVR12 n = 14 DCV + SOF SVR12 n = 14 DCV + SOF + RBV SVR12 Rx Naïve GT 1a/1b n = 44 n = 15 SOF × 7 days, then DCV + SOF SVR12 n = 14 DCV + SOF SVR12 n = 15 DCV + SOF + RBV SVR12 Drug Dosing Daclatasvir (DCV): 60 mg once daily Sofosbuvir (SOF): 400 mg once daily Ribavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg) Ribavirin (RBV): GT 2 or 3 (800 mg/day) N =14 Source: Sulkowski MS, et al. N Engl J Med. 2014;370:

47 SVR12 by GT 3, by Treatment Regimen
Daclatasvir + Sofosbuvir +/- Ribavirin for HCV GT 1-3 A : Subset Analysis for Treatment-Naïve GT 3 SVR12 by GT 3, by Treatment Regimen 5/7 6/6 5/5 DCV = daclatasvir; SOF = sofosbuvir; RBV = ribavirin Source: Sulkowski MS, et al. N Engl J Med. 2014;370:

48 Summary Points for Treatment of Chronic HCV GT-3
Treat now with Sofosbuvir + Ribavirin x 24 weeks Consider IFN-based Rx in select patient who can tolerate IFN to shorten therapy, save costs and have a nominally higher SVR rate Stage patient for liver disease and systemic disease Look for signs of fatty liver and metabolic syndrome GT 3 may be the new “GT 1” but high SVR rates can be seen in selected patients

49 This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention.

Download ppt "Treatment of Chronic HCV Genotype 3"

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.

The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 1 Robert G. Gish MD Staff Physician, Stanford University.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 1 Robert G. Gish MD Staff Physician, Stanford University.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4 PHOTON-2 Trial Phase 3 Molina JM, et al. IAC. 2014;

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4 PHOTON-2 Trial Phase 3 Molina JM, et al. IAC. 2014;
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.
Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract.

Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.
Hepatitis web study Hepatitis web study Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2 Phase 2 Treatment Naïve and Treatment Experienced Source:

Hepatitis web study Hepatitis web study Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2 Phase 2 Treatment Naïve and Treatment Experienced Source:
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A1444-040 Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.

Similar presentations

Ads by Google